No Data
No Data
Increased support for innovative drugs, the collective rise of the innovative drug sector, sino biopharm (01177) rose 4.5%.
Jingu Finance News | The innovative drug sector as a whole is on the rise, with Lai Kai Medicine (02105) up 6.07%, Sino Biopharm (01177) up 4.5%, Genscript Bio (01548) up 4.07%, Hutchmed (China) (00013) up 2.68%, and Innovent Bio (01801) up 2.1%. The State Council Information Office held a series of themed press conferences on 'Promoting High-Quality Development', and Li Li, Director of the National Medical Products Administration, stated at the conference the increased support for pharmaceutical R&D innovation. This includes the evaluation and approval, inspection and verification of innovative drugs and medical instruments that are key to the country's support.
Press Release: GenScript Appoints New Board Members to Drive Global Growth
Genscript Bio (01548.HK): Ross Allen Grossman appointed as a non-executive director.
On September 12th, GLI announced that the Board of Directors is pleased to announce the appointment of Ross Allen Grossman and Alphonse Galdes as non-executive directors and independent non-executive directors of GeneScript Bio Limited, effective from September 12th, 2024.
Genscript Bio [01548] is now trading at HKD 10.46, a decrease of 13.84%.
As of 11:48, Genscript Bio [01548] reported a price of 10.46 Hong Kong dollars, a decrease of 1.68 Hong Kong dollars or 13.84% from yesterday's closing price of 12.14 Hong Kong dollars. The turnover was 176.858 million Hong Kong dollars, with today's highest price at 10.78 Hong Kong dollars and the lowest price at 10.08 Hong Kong dollars. Based on the closing price of yesterday, the 10-day average price is 11.62 Hong Kong dollars, and the 50-day average price is 12.95 Hong Kong dollars. The current pe ratio is -29.47 times, and the 14-day relative strength index is 25.96.
HK stocks surge | Genscript Bio (01548) rose nearly 4%, legend biotech's 'Siddarioncel' has been approved for domestic listing.
Genscript Bio (01548) rose nearly 4%, as of press time, up 3.79%, at HK$12.04, with a turnover of HK$39.6598 million.
Hong Kong stock concept tracking | 6 domestic CAR-T anti-cancer drugs approved, market is concerned whether CAR-T therapy can enter medical insurance this year (attached concept stock)
The "miracle drug" CAR-T therapy, which costs one million yuan per injection, has made continuous progress in China recently.
No Data
No Data